TG Therapeutics
Agent30Agent Readiness: 30/100. Below median. Measured by StartupHub.ai. Median 41.Trust82Data Trust: 82/100. Top 25%. Measured by StartupHub.ai. Median 61.A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.
About
TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with B-cell malignancies and autoimmune diseases. The company's pipeline includes a combination of novel small molecules and antibodies designed to target key pathways involved in these diseases. Their lead programs, ublituximab and umbralisib, are being investigated in various hematologic cancers and autoimmune conditions.
Listed competitors
Develops, manufactures, and markets radiopharmaceuticals for diagnostic and therapeutic applications.
Global biopharmaceutical company focused on oncology and neuroscience treatments.
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Also in this space
Biotechnology company focused on developing cancer immunotherapies.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Shares Biotechnology, Pharmaceuticals
Developing novel therapeutics to restore gut lymphatic function.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- tgtherapeutics.com
- Headquarters
- New York, New York, USA
- Founded
- 2011
- Employees
- 497
- Total funding
- $360M (Public Stock Offering)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 15 Dec 2020 | Public Stock Offering | $275M | |
| 5 May 2020 | At-the-Market | $60M | |
| 29 Feb 2012 | Post-IPO capital | $25M |
Tech stack
Detected on tgtherapeutics.com, last scanned 1 Nov 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4, Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
- Cookie consent
- OneTrust
TG Therapeutics scores 58. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is TG Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for TG Therapeutics is 82 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has TG Therapeutics raised?
TG Therapeutics has raised a total of $360M in funding. The most recent round on record is Public Stock Offering.
How many employees does TG Therapeutics have?
TG Therapeutics has approximately 497 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for TG Therapeutics
